查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2070374

Pembrolizumab市場規模、佔有率、成長率、全球產業分析、區域趨勢及2026年至2034年預測。

Pembrolizumab Market Size, Share, Growth, Global Industry Analysis, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 190 Pages | 商品交期: 2-3個工作天內

價格

Pembrolizumab市場成長要素

全球Pembrolizumab市場預計在2025年達到317億美元，並從2026年的331億美元成長至2034年的411億美元，預測期間內複合年成長率（CAGR）為2.74%。Pembrolizumab主要以「KEYTRUDA」為商品名上市，是目前用於治療多種癌症的領先免疫腫瘤療法之一。該藥物透過幫助免疫系統識別並攻擊癌細胞發揮作用。

受臨床實踐中積極應用、適應症不斷擴大、早期治療中應用日益廣泛以及對基於生物標記的癌症療法的需求不斷成長的推動，該市場正穩步成長。到2025年，北美將以52.77%的市場佔有率引領市場，這得益於其較高的癌症發病率、先進的腫瘤治療基礎設施、廣泛的生物標記檢測以及完善的保險覆蓋。

Pembrolizumab市場趨勢

免疫療法在標準癌症治療中的作用日益增強，這是市場的關鍵趨勢。Pembrolizumab不僅擴大用於晚期和轉移性癌症，也擴大用於早期癌症和手術全期治療。這種廣泛的應用增強了醫生的信心，並擴大了合格患者群體。

2025年6月，默克公司獲得美國FDA批准，KEYTRUDA可用於PD-L1陽性、可切除的局部晚期頭頸部鱗狀細胞癌的新輔助和輔助治療。這進一步深化了該藥物在結構化癌症治療路徑中的作用。

市場促進因素

市場成長的主要驅動力是全球癌症負擔的日益加重。肺癌、乳癌、大腸癌、腎臟癌、膀胱癌、頭頸癌和婦科癌症病例的不斷增加，推動了對先進全身療法的需求。Pembrolizumab已獲準用於多種腫瘤類型，這為其廣泛的臨床應用提供了支持。診斷率的提高、生物標記檢測的普及以及早期治療性介入，也促進了符合治療條件的患者群體的擴大。

市場限制因素

高昂的治療費用和保險報銷壓力仍然是主要限制因素。Pembrolizumab是一種昂貴的生物製藥，在醫療技術評估嚴格且醫療預算有限的國家，患者獲得治療的機會可能會被延遲。即使在獲得監管部門批准後，關於保險報銷、價格調整和保險公司限制的談判也可能導致藥物上市延遲，尤其是在對成本敏感的市場。

市場機遇

帕博利珠單抗適應症的持續擴展，涵蓋多種腫瘤類型，帶來了強勁的成長機會。隨著每一項新適應症的獲批，Pembrolizumab單抗可望拓展至更多癌症適應症、治療線或患者亞群。 2026年2月，默克宣布批准KEYTRUDA和KEYTRUDA QLEX合併紫杉醇（可合併或不合併Bevacizumab）用於治療部分PD-L1陽性鉑金抗藥性的卵巢、輸卵管癌或原發性腹膜癌成人患者。此次適應症的擴展將進一步提升含鉑類藥物單抗在婦科腫瘤領域的應用。

市場挑戰

主要挑戰在於生物相似藥的興起以及專利到期帶來的日益成長的壓力。Pembrolizumab是一種高價值的生物製藥，全球銷售額很高，因此生物相似藥研發公司正積極進入這一領域。如果未來生物相似藥上市，價格壓力將會增加，市場獨佔期將會縮短，原廠藥的長期銷售成長可能會受到影響。 2025年6月，瑞迪博士實驗室和阿博特克公司宣佈建立合作關係，共同開發和商業化面向全球市場的Pembrolizumab單抗生物相似藥。

區域分析

預計北美將引領全球市場，到 2025 年將達到 167.3 億美元，高於 2024 年的 157.7 億美元。美國市場預計到 2026 年將達到 156.4 億美元，約佔全球銷售額的 47.24%。

預計到2026年，歐洲市場規模將達到76億美元，年增2.26%。英國市場規模預計為13.8億美元，德國市場預計到2026年將達到17億美元。

亞太地區癌症患者數量眾多，抗癌藥物的可近性也得到改善，預計到 2026 年，該地區癌症市場規模將達到 62.4 億美元。其中，預計到 2026 年，中國市場規模將達到 21.6 億美元，日本市場規模將達到 14.6 億美元，印度市場規模將達到 5.1 億美元。

預計到2026年，拉丁美洲市場規模將達到10.9億美元，海灣合作理事會（GCC）市場規模預計為4億美元。南非市場預計到2026年將達到1.9億美元。

目錄

第1章：引言

第2章摘要整理

第3章 市場動態

  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第4章：主要考慮因素

  • 新產品發布：按主要公司分類
  • 產業重大發展動態（合併、收購、合作、新產品和服務的推出等）
  • 主要國家/地區的法規和還款狀況
  • 大型公司管道分析

第5章：2021-2034年全球Pembrolizumab市場分析、洞察與預測

  • 市場分析、洞察與預測：按產品類型分類
    • KEYTRUDA IV
    • KEYTRUDA QLEX/SCPembrolizumab
  • 市場分析、洞察與預測：按疾病適應症分類
    • NSCLC
    • 黑色素瘤
    • HNSCC
    • 尿路上皮癌
    • RCC
    • TNBC
    • 胃癌/胃食道交界處癌/食道癌
    • 子宮頸癌
    • 其他
  • 市場分析、洞察與預測：按年齡層別分類
    • 兒童
    • 成人
  • 市場分析、洞察與預測：按類型
    • 品牌
    • 生物相似藥
  • 市場分析、洞察與預測：按治療場所分類
    • 早期/圍手術全期手術全期
    • 晚期/轉移性
    • 其他
  • 市場分析、洞察與預測：按給藥途徑
    • IV
    • SC
  • 市場分析、洞察與預測：按最終用戶分類
    • 醫院
    • 專科癌症診所
    • 門診靜脈輸液治療中心
    • 其他
  • 分析、洞察與預測：按地區分類
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第6章：北美Pembrolizumab市場分析、洞察與預測（2021-2034年）

  • 國家
    • 美國
    • 加拿大

第7章：歐洲Pembrolizumab市場分析、洞察與預測（2021-2034年）

  • 國家
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 斯堪地那維亞
    • 其他歐洲國家

第8章：2021-2034年亞太地區Pembrolizumab市場分析、洞察與預測

  • 國家
    • 中國
    • 日本
    • 印度
    • 東南亞
    • 澳洲
    • 其他亞太國家

第9章：2021-2034年拉丁美洲Pembrolizumab市場分析、洞察與預測

  • 國家
    • 巴西
    • 墨西哥
    • 其他拉丁美洲國家

第10章：Pembrolizumab市場分析、洞察及預測（中東及非洲，2021-2034年）

  • 國家
    • GCC
    • 南非
    • 其他中東和非洲國家

第11章 競爭分析

  • 全球市佔率分析（2025 年）
  • 公司簡介
    • Merck & Co., Inc.
    • Samsung Bioepis Co., Ltd.
    • Sandoz AG
    • Celltrion, Inc.
    • Shanghai Henlius Biotech, Inc.
    • Bio-Thera Solutions, Ltd.
    • Dr. Reddy's Laboratories Ltd.
    • Alvotech
    • Biocon Biologics Limited
    • Organon & Co.
Product Code: FBI115937

Growth Factors of pembrolizumab Market

The global pembrolizumab market was valued at USD 31.70 billion in 2025 and is projected to grow from USD 33.10 billion in 2026 to USD 41.10 billion by 2034, registering a CAGR of 2.74% during the forecast period. Pembrolizumab, marketed mainly as KEYTRUDA, is one of the leading immuno-oncology therapies used across several cancer types. It works by helping the immune system recognize and attack cancer cells.

The market is growing steadily due to strong clinical adoption, continued label expansions, rising use in earlier treatment settings, and increasing demand for biomarker-driven cancer therapy. North America dominated the market in 2025 with a 52.77% market share, supported by high cancer incidence, advanced oncology infrastructure, broad biomarker testing, and strong reimbursement access.

Pembrolizumab Market Trends

A key trend in the market is the growing role of immunotherapy in standard cancer care. Pembrolizumab is increasingly being used not only in advanced and metastatic cancer but also in earlier-stage and perioperative treatment settings. This wider integration is strengthening physician confidence and expanding the eligible patient base.

In June 2025, Merck received U.S. FDA approval for KEYTRUDA in PD-L1 positive resectable locally advanced head and neck squamous cell carcinoma as neoadjuvant and adjuvant treatment, showing its deeper role in structured cancer treatment pathways.

Market Drivers

The major driver of market growth is the rising global cancer burden. Increasing cases of lung, breast, colorectal, kidney, bladder, head and neck, and gynecologic cancers are driving demand for advanced systemic therapies. Pembrolizumab has approvals across multiple tumor types, which supports its broad clinical use. Growing diagnosis rates, wider biomarker testing, and earlier treatment intervention are also increasing the eligible treatment population.

Market Restraints

High treatment cost and reimbursement pressure remain key restraints. Pembrolizumab is a premium-priced biologic therapy, and access can be delayed in countries with strict health technology assessments and limited healthcare budgets. Reimbursement negotiations, pricing reviews, and payer restrictions can slow adoption even after regulatory approval, especially in cost-sensitive markets.

Market Opportunities

Continuous label expansion across multiple tumor types presents strong growth opportunities. Each new approval allows pembrolizumab to enter additional cancer settings, treatment lines, or patient subgroups. In February 2026, Merck announced approval for KEYTRUDA and KEYTRUDA QLEX with paclitaxel, with or without bevacizumab, for certain adults with PD-L1-positive platinum-resistant ovarian, fallopian tube, or primary peritoneal carcinoma. This expansion supports deeper penetration in gynecologic oncology.

Market Challenges

The main challenge is rising biosimilar and patent-cliff pressure. Since pembrolizumab is a high-value biologic with large global sales, biosimilar developers are actively entering the space. Future biosimilar launches may create pricing pressure, reduce market exclusivity, and affect long-term revenue growth for the originator brand. In June 2025, Dr. Reddy's and Alvotech announced a collaboration to co-develop and commercialize a pembrolizumab biosimilar for global markets.

Segment Analysis

By product type, the market is segmented into KEYTRUDA IV and KEYTRUDA QLEX/subcutaneous pembrolizumab. KEYTRUDA IV dominated the market due to its long-established use, strong clinical familiarity, infusion-based workflows, and broad adoption across tumor types. KEYTRUDA QLEX is expected to grow at a CAGR of 20.44% due to its convenient subcutaneous administration.

By disease indication, the NSCLC segment dominated in 2025 due to high disease burden and strong pembrolizumab adoption across advanced and earlier-stage lung cancer. The others segment is projected to grow at a CAGR of 4.93%.

By age group, the adult segment dominated the market in 2025, as most approved indications and commercial use are concentrated in adult solid tumors. The pediatric segment is projected to grow at a CAGR of 6.01%.

By type, the branded segment led the market, supported by KEYTRUDA's strong global approval base and absence of marketed biosimilar competition. The biosimilar segment is expected to grow at a CAGR of 45.90% during the study period.

By therapy setting, advanced/metastatic disease dominated due to pembrolizumab's long-standing use in late-stage oncology. The early-stage/perioperative segment is projected to grow at a CAGR of 6.27%.

By route of administration, the IV segment dominated, while the SC segment is emerging with new approvals. By end user, specialty cancer clinics led the market due to strong oncology expertise, biomarker-based treatment decisions, and immunotherapy administration capabilities.

Regional Analysis

North America led the global market with USD 16.73 billion in 2025, increasing from USD 15.77 billion in 2024. The U.S. market is estimated to reach USD 15.64 billion in 2026, accounting for about 47.24% of global revenue.

Europe is projected to reach USD 7.60 billion in 2026, growing at 2.26%. The U.K. market is estimated at USD 1.38 billion, while Germany is expected to reach USD 1.70 billion in 2026.

Asia Pacific is expected to reach USD 6.24 billion in 2026, supported by a large cancer patient base and improving access to oncology medicines. China is projected at USD 2.16 billion, Japan at USD 1.46 billion, and India at USD 0.51 billion in 2026.

Latin America is set to reach USD 1.09 billion in 2026, while the GCC market is projected at USD 0.40 billion. South Africa is expected to reach USD 0.19 billion in 2026.

Competitive Landscape

The global market is highly consolidated, led by Merck & Co., Inc. Other key players include Samsung Bioepis, Sandoz, Celltrion, Shanghai Henlius Biotech, Bio-Thera Solutions, Dr. Reddy's Laboratories, Alvotech, Biocon Biologics, and Organon. Companies are focusing on regulatory approvals, biosimilar development, partnerships, and new formulations.

Conclusion

The pembrolizumab market is projected to grow from USD 31.70 billion in 2025 to USD 33.10 billion in 2026, reaching USD 41.10 billion by 2034. Growth will be supported by label expansion, rising cancer incidence, biomarker-driven therapy adoption, and subcutaneous formulation launches. However, high treatment costs, reimbursement barriers, and future biosimilar competition may moderate long-term growth.

Segmentation By Product Type, Disease Indication, Age Group, Type, Therapy Setting, Route of Administration, End User, and Region

By Product Type * KEYTRUDA IV

  • KEYTRUDA QLEX / SC Pembrolizumab

By Disease Indication * NSCLC

  • Melanoma
  • HNSCC
  • Urothelial Carcinoma
  • RCC
  • TNBC
  • Gastric/GEJ/Esophageal Cancers
  • Cervical Cancer
  • Others

By Age Group * Pediatric

  • Others

By Type * Branded

  • Biosimilar

By Therapy Setting * Early-stage / Perioperative

  • Advanced / Metastatic
  • Others

By Route of Administration * IV

  • SC

By End User * Hospitals

  • Specialty Cancer Clinics
  • Ambulatory Infusion Centers
  • Others

By Region * North America (By Product Type, Disease Indication, Age Group, Type, Therapy Setting, Route of Administration, End User, and Country)

    • U.S.
    • Canada
  • Europe (By Product Type, Disease Indication, Age Group, Type, Therapy Setting, Route of Administration, End User, and Country/Sub-region)
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Product Type, Disease Indication, Age Group, Type, Therapy Setting, Route of Administration, End User, and Country/Sub-region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Product Type, Disease Indication, Age Group, Type, Therapy Setting, Route of Administration, End User, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Product Type, Disease Indication, Age Group, Type, Therapy Setting, Route of Administration, End User, and Country/Sub-region)
    • GCC
    • South Africa
    • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. New Product Launches, By Key Players
  • 4.2. Key Industry Developments (Mergers, Acquisitions, Partnerships, Launches, etc.)
  • 4.3. Regulatory & Reimbursement Scenario, By Key Countries/Regions
  • 4.4. Pipeline Analysis, By Key Players

5. Global Pembrolizumab Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Product Type
    • 5.1.1. KEYTRUDA IV
    • 5.1.2. KEYTRUDA QLEX / SC Pembrolizumab
  • 5.2. Market Analysis, Insights and Forecast - By Disease Indication
    • 5.2.1. NSCLC
    • 5.2.2. Melanoma
    • 5.2.3. HNSCC
    • 5.2.4. Urothelial Carcinoma
    • 5.2.5. RCC
    • 5.2.6. TNBC
    • 5.2.7. Gastric/GEJ/Esophageal Cancers
    • 5.2.8. Cervical Cancer
    • 5.2.9. Others
  • 5.3. Market Analysis, Insights and Forecast - By Age Group
    • 5.3.1. Pediatric
    • 5.3.2. Adults
  • 5.4. Market Analysis, Insights and Forecast - By Type
    • 5.4.1. Branded
    • 5.4.2. Biosimilar
  • 5.5. Market Analysis, Insights and Forecast - By Therapy Setting
    • 5.5.1. Early-stage / Perioperative
    • 5.5.2. Advanced / Metastatic
    • 5.5.3. Others
  • 5.6. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.6.1. IV
    • 5.6.2. SC
  • 5.7. Market Analysis, Insights and Forecast - By End User
    • 5.7.1. Hospitals
    • 5.7.2. Specialty Cancer Clinics
    • 5.7.3. Ambulatory Infusion Centers
    • 5.7.4. Others
  • 5.8. Market Analysis, Insights and Forecast - Region
    • 5.8.1. North America
    • 5.8.2. Europe
    • 5.8.3. Asia Pacific
    • 5.8.4. Latin America
    • 5.8.5. Middle East & Africa

6. North America Pembrolizumab Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Product Type
    • 6.1.1. KEYTRUDA IV
    • 6.1.2. KEYTRUDA QLEX / SC Pembrolizumab
  • 6.2. Market Analysis, Insights and Forecast - By Disease Indication
    • 6.2.1. NSCLC
    • 6.2.2. Melanoma
    • 6.2.3. HNSCC
    • 6.2.4. Urothelial Carcinoma
    • 6.2.5. RCC
    • 6.2.6. TNBC
    • 6.2.7. Gastric/GEJ/Esophageal Cancers
    • 6.2.8. Cervical Cancer
    • 6.2.9. Others
  • 6.3. Market Analysis, Insights and Forecast - By Age Group
    • 6.3.1. Pediatric
    • 6.3.2. Adults
  • 6.4. Market Analysis, Insights and Forecast - By Type
    • 6.4.1. Branded
    • 6.4.2. Biosimilar
  • 6.5. Market Analysis, Insights and Forecast - By Therapy Setting
    • 6.5.1. Early-stage / Perioperative
    • 6.5.2. Advanced / Metastatic
    • 6.5.3. Others
  • 6.6. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.6.1. IV
    • 6.6.2. SC
  • 6.7. Market Analysis, Insights and Forecast - By End User
    • 6.7.1. Hospitals
    • 6.7.2. Specialty Cancer Clinics
    • 6.7.3. Ambulatory Infusion Centers
    • 6.7.4. Others
  • 6.8. Market Analysis, Insights and Forecast - By Country
    • 6.8.1. U.S.
    • 6.8.2. Canada

7. Europe Pembrolizumab Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Product Type
    • 7.1.1. KEYTRUDA IV
    • 7.1.2. KEYTRUDA QLEX / SC Pembrolizumab
  • 7.2. Market Analysis, Insights and Forecast - By Disease Indication
    • 7.2.1. NSCLC
    • 7.2.2. Melanoma
    • 7.2.3. HNSCC
    • 7.2.4. Urothelial Carcinoma
    • 7.2.5. RCC
    • 7.2.6. TNBC
    • 7.2.7. Gastric/GEJ/Esophageal Cancers
    • 7.2.8. Cervical Cancer
    • 7.2.9. Others
  • 7.3. Market Analysis, Insights and Forecast - By Age Group
    • 7.3.1. Pediatric
    • 7.3.2. Adults
  • 7.4. Market Analysis, Insights and Forecast - By Type
    • 7.4.1. Branded
    • 7.4.2. Biosimilar
  • 7.5. Market Analysis, Insights and Forecast - By Therapy Setting
    • 7.5.1. Early-stage / Perioperative
    • 7.5.2. Advanced / Metastatic
    • 7.5.3. Others
  • 7.6. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.6.1. IV
    • 7.6.2. SC
  • 7.7. Market Analysis, Insights and Forecast - By End User
    • 7.7.1. Hospitals
    • 7.7.2. Specialty Cancer Clinics
    • 7.7.3. Ambulatory Infusion Centers
    • 7.7.4. Others
  • 7.8. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.8.1. U.K.
    • 7.8.2. Germany
    • 7.8.3. France
    • 7.8.4. Italy
    • 7.8.5. Spain
    • 7.8.6. Scandinavia
    • 7.8.7. Rest of Europe

8. Asia Pacific Pembrolizumab Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Product Type
    • 8.1.1. KEYTRUDA IV
    • 8.1.2. KEYTRUDA QLEX / SC Pembrolizumab
  • 8.2. Market Analysis, Insights and Forecast - By Disease Indication
    • 8.2.1. NSCLC
    • 8.2.2. Melanoma
    • 8.2.3. HNSCC
    • 8.2.4. Urothelial Carcinoma
    • 8.2.5. RCC
    • 8.2.6. TNBC
    • 8.2.7. Gastric/GEJ/Esophageal Cancers
    • 8.2.8. Cervical Cancer
    • 8.2.9. Others
  • 8.3. Market Analysis, Insights and Forecast - By Age Group
    • 8.3.1. Pediatric
    • 8.3.2. Adults
  • 8.4. Market Analysis, Insights and Forecast - By Type
    • 8.4.1. Branded
    • 8.4.2. Biosimilar
  • 8.5. Market Analysis, Insights and Forecast - By Therapy Setting
    • 8.5.1. Early-stage / Perioperative
    • 8.5.2. Advanced / Metastatic
    • 8.5.3. Others
  • 8.6. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.6.1. IV
    • 8.6.2. SC
  • 8.7. Market Analysis, Insights and Forecast - By End User
    • 8.7.1. Hospitals
    • 8.7.2. Specialty Cancer Clinics
    • 8.7.3. Ambulatory Infusion Centers
    • 8.7.4. Others
  • 8.8. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.8.1. China
    • 8.8.2. Japan
    • 8.8.3. India
    • 8.8.4. Southeast Asia
    • 8.8.5. Australia
    • 8.8.6. Rest of Asia Pacific

9. Latin America Pembrolizumab Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Product Type
    • 9.1.1. KEYTRUDA IV
    • 9.1.2. KEYTRUDA QLEX / SC Pembrolizumab
  • 9.2. Market Analysis, Insights and Forecast - By Disease Indication
    • 9.2.1. NSCLC
    • 9.2.2. Melanoma
    • 9.2.3. HNSCC
    • 9.2.4. Urothelial Carcinoma
    • 9.2.5. RCC
    • 9.2.6. TNBC
    • 9.2.7. Gastric/GEJ/Esophageal Cancers
    • 9.2.8. Cervical Cancer
    • 9.2.9. Others
  • 9.3. Market Analysis, Insights and Forecast - By Age Group
    • 9.3.1. Pediatric
    • 9.3.2. Adults
  • 9.4. Market Analysis, Insights and Forecast - By Type
    • 9.4.1. Branded
    • 9.4.2. Biosimilar
  • 9.5. Market Analysis, Insights and Forecast - By Therapy Setting
    • 9.5.1. Early-stage / Perioperative
    • 9.5.2. Advanced / Metastatic
    • 9.5.3. Others
  • 9.6. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.6.1. IV
    • 9.6.2. SC
  • 9.7. Market Analysis, Insights and Forecast - By End User
    • 9.7.1. Hospitals
    • 9.7.2. Specialty Cancer Clinics
    • 9.7.3. Ambulatory Infusion Centers
    • 9.7.4. Others
  • 9.8. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.8.1. Brazil
    • 9.8.2. Mexico
    • 9.8.3. Rest of Latin America

10. Middle East & Africa Pembrolizumab Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Product Type
    • 10.1.1. KEYTRUDA IV
    • 10.1.2. KEYTRUDA QLEX / SC Pembrolizumab
  • 10.2. Market Analysis, Insights and Forecast - By Disease Indication
    • 10.2.1. NSCLC
    • 10.2.2. Melanoma
    • 10.2.3. HNSCC
    • 10.2.4. Urothelial Carcinoma
    • 10.2.5. RCC
    • 10.2.6. TNBC
    • 10.2.7. Gastric/GEJ/Esophageal Cancers
    • 10.2.8. Cervical Cancer
    • 10.2.9. Others
  • 10.3. Market Analysis, Insights and Forecast - By Age Group
    • 10.3.1. Pediatric
    • 10.3.2. Adults
  • 10.4. Market Analysis, Insights and Forecast - By Type
    • 10.4.1. Branded
    • 10.4.2. Biosimilar
  • 10.5. Market Analysis, Insights and Forecast - By Therapy Setting
    • 10.5.1. Early-stage / Perioperative
    • 10.5.2. Advanced / Metastatic
    • 10.5.3. Others
  • 10.6. Market Analysis, Insights and Forecast - By Route of Administration
    • 10.6.1. IV
    • 10.6.2. SC
  • 10.7. Market Analysis, Insights and Forecast - By End User
    • 10.7.1. Hospitals
    • 10.7.2. Specialty Cancer Clinics
    • 10.7.3. Ambulatory Infusion Centers
    • 10.7.4. Others
  • 10.8. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.8.1. GCC
    • 10.8.2. South Africa
    • 10.8.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. Merck & Co., Inc.
    • 11.2.2. Samsung Bioepis Co., Ltd.
    • 11.2.3. Sandoz AG
    • 11.2.4. Celltrion, Inc.
    • 11.2.5. Shanghai Henlius Biotech, Inc.
    • 11.2.6. Bio-Thera Solutions, Ltd.
    • 11.2.7. Dr. Reddy's Laboratories Ltd.
    • 11.2.8. Alvotech
    • 11.2.9. Biocon Biologics Limited
    • 11.2.10. Organon & Co.

List of Tables

  • Figure 1: Global Pembrolizumab Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Pembrolizumab Market Value Share (%), by Product Type, 2025 & 2034
  • Figure 3: Global Pembrolizumab Market Value Share (%), by Disease Indication, 2025 & 2034
  • Figure 4: Global Pembrolizumab Market Value Share (%), by Age Group, 2025 & 2034
  • Figure 5: Global Pembrolizumab Market Value Share (%), by Type, 2025 & 2034
  • Figure 6: Global Pembrolizumab Market Value Share (%), by Therapy Setting, 2025 & 2034
  • Figure 7: Global Pembrolizumab Market Value Share (%), by Route of Administration, 2025 & 2034
  • Figure 8: Global Pembrolizumab Market Value Share (%), by End User, 2025 & 2034
  • Figure 9: Global Pembrolizumab Market Value Share (%), by Region, 2025 & 2034
  • Figure 10: North America Pembrolizumab Market Value (USD billion), by Product Type, 2025 & 2034
  • Figure 11: North America Pembrolizumab Market Value Share (%), by Product Type, 2025
  • Figure 12: North America Pembrolizumab Market Value (USD billion), by Disease Indication, 2025 & 2034
  • Figure 13: North America Pembrolizumab Market Value Share (%), by Disease Indication, 2025
  • Figure 14: North America Pembrolizumab Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 15: North America Pembrolizumab Market Value Share (%), by Age Group, 2025
  • Figure 16: North America Pembrolizumab Market Value (USD billion), by Type, 2025 & 2034
  • Figure 17: North America Pembrolizumab Market Value Share (%), by Type, 2025
  • Figure 18: North America Pembrolizumab Market Value (USD billion), by Therapy Setting, 2025 & 2034
  • Figure 19: North America Pembrolizumab Market Value Share (%), by Therapy Setting, 2025
  • Figure 20: North America Pembrolizumab Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 21: North America Pembrolizumab Market Value Share (%), by Route of Administration, 2025
  • Figure 22: North America Pembrolizumab Market Value (USD billion), by End User, 2025 & 2034
  • Figure 23: North America Pembrolizumab Market Value Share (%), by End User, 2025
  • Figure 24: North America Pembrolizumab Market Value (USD billion), by Country, 2025 & 2034
  • Figure 25: North America Pembrolizumab Market Value Share (%), by Country, 2025
  • Figure 26: Europe Pembrolizumab Market Value (USD billion), by Product Type, 2025 & 2034
  • Figure 27: Europe Pembrolizumab Market Value Share (%), by Product Type, 2025
  • Figure 28: Europe Pembrolizumab Market Value (USD billion), by Disease Indication, 2025 & 2034
  • Figure 29: Europe Pembrolizumab Market Value Share (%), by Disease Indication, 2025
  • Figure 30: Europe Pembrolizumab Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 31: Europe Pembrolizumab Market Value Share (%), by Age Group, 2025
  • Figure 32: Europe Pembrolizumab Market Value (USD billion), by Type, 2025 & 2034
  • Figure 33: Europe Pembrolizumab Market Value Share (%), by Type, 2025
  • Figure 34: Europe Pembrolizumab Market Value (USD billion), by Therapy Setting, 2025 & 2034
  • Figure 35: Europe Pembrolizumab Market Value Share (%), by Therapy Setting, 2025
  • Figure 36: Europe Pembrolizumab Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 37: Europe Pembrolizumab Market Value Share (%), by Route of Administration, 2025
  • Figure 38: Europe Pembrolizumab Market Value (USD billion), by End User, 2025 & 2034
  • Figure 39: Europe Pembrolizumab Market Value Share (%), by End User, 2025
  • Figure 40: Europe Pembrolizumab Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 41: Europe Pembrolizumab Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 42: Asia Pacific Pembrolizumab Market Value (USD billion), by Product Type, 2025 & 2034
  • Figure 43: Asia Pacific Pembrolizumab Market Value Share (%), by Product Type, 2025
  • Figure 44: Asia Pacific Pembrolizumab Market Value (USD billion), by Disease Indication, 2025 & 2034
  • Figure 45: Asia Pacific Pembrolizumab Market Value Share (%), by Disease Indication, 2025
  • Figure 46: Asia Pacific Pembrolizumab Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 47: Asia Pacific Pembrolizumab Market Value Share (%), by Age Group, 2025
  • Figure 48: Asia Pacific Pembrolizumab Market Value (USD billion), by Type, 2025 & 2034
  • Figure 49: Asia Pacific Pembrolizumab Market Value Share (%), by Type, 2025
  • Figure 50: Asia Pacific Pembrolizumab Market Value (USD billion), by Therapy Setting, 2025 & 2034
  • Figure 51: Asia Pacific Pembrolizumab Market Value Share (%), by Therapy Setting, 2025
  • Figure 52: Asia Pacific Pembrolizumab Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 53: Asia Pacific Pembrolizumab Market Value Share (%), by Route of Administration, 2025
  • Figure 54: Asia Pacific Pembrolizumab Market Value (USD billion), by End User, 2025 & 2034
  • Figure 55: Asia Pacific Pembrolizumab Market Value Share (%), by End User, 2025
  • Figure 56: Asia Pacific Pembrolizumab Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 57: Asia Pacific Pembrolizumab Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 58: Latin America Pembrolizumab Market Value (USD billion), by Product Type, 2025 & 2034
  • Figure 59: Latin America Pembrolizumab Market Value Share (%), by Product Type, 2025
  • Figure 60: Latin America Pembrolizumab Market Value (USD billion), by Disease Indication, 2025 & 2034
  • Figure 61: Latin America Pembrolizumab Market Value Share (%), by Disease Indication, 2025
  • Figure 62: Latin America Pembrolizumab Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 63: Latin America Pembrolizumab Market Value Share (%), by Age Group, 2025
  • Figure 64: Latin America Pembrolizumab Market Value (USD billion), by Type, 2025 & 2034
  • Figure 65: Latin America Pembrolizumab Market Value Share (%), by Type, 2025
  • Figure 66: Latin America Pembrolizumab Market Value (USD billion), by Therapy Setting, 2025 & 2034
  • Figure 67: Latin America Pembrolizumab Market Value Share (%), by Therapy Setting, 2025
  • Figure 68: Latin America Pembrolizumab Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 69: Latin America Pembrolizumab Market Value Share (%), by Route of Administration, 2025
  • Figure 70: Latin America Pembrolizumab Market Value (USD billion), by End User, 2025 & 2034
  • Figure 71: Latin America Pembrolizumab Market Value Share (%), by End User, 2025
  • Figure 72: Latin America Pembrolizumab Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 73: Latin America Pembrolizumab Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 74: Middle East & Africa Pembrolizumab Market Value (USD billion), by Product Type, 2025 & 2034
  • Figure 75: Middle East & Africa Pembrolizumab Market Value Share (%), by Product Type, 2025
  • Figure 76: Middle East & Africa Pembrolizumab Market Value (USD billion), by Disease Indication, 2025 & 2034
  • Figure 77: Middle East & Africa Pembrolizumab Market Value Share (%), by Disease Indication, 2025
  • Figure 78: Middle East & Africa Pembrolizumab Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 79: Middle East & Africa Pembrolizumab Market Value Share (%), by Age Group, 2025
  • Figure 80: Middle East & Africa Pembrolizumab Market Value (USD billion), by Type, 2025 & 2034
  • Figure 81: Middle East & Africa Pembrolizumab Market Value Share (%), by Type, 2025
  • Figure 82: Middle East & Africa Pembrolizumab Market Value (USD billion), by Therapy Setting, 2025 & 2034
  • Figure 83: Middle East & Africa Pembrolizumab Market Value Share (%), by Therapy Setting, 2025
  • Figure 84: Middle East & Africa Pembrolizumab Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 85: Middle East & Africa Pembrolizumab Market Value Share (%), by Route of Administration, 2025
  • Figure 86: Middle East & Africa Pembrolizumab Market Value (USD billion), by End User, 2025 & 2034
  • Figure 87: Middle East & Africa Pembrolizumab Market Value Share (%), by End User, 2025
  • Figure 88: Middle East & Africa Pembrolizumab Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 89: Middle East & Africa Pembrolizumab Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 90: Global Pembrolizumab Market Share (%), by Company, 2025